We are live on ! Find out more
ANTX icon

AN2 Therapeutics
ANTX

45 hedge funds and large institutions have $41.7M invested in AN2 Therapeutics in 2024 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 14 increasing their positions, 13 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.1% more ownership

Funds ownership: 62.99% → 65.09% (+2.1%)

8% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 13

17% less funds holding

Funds holding: 54 → 45 (-9)

31% less capital invested

Capital invested by funds: $60.9M → $41.7M (-$19.1M)

57% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 14

Holders
45
Holders Change
-9
Holders Change %
-16.67%
% of All Funds
0.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
14
Reduced
13
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
OCA
Octagon Capital Advisors
New York
+$5.04M
2
FLSM
Frazier Life Sciences Management
California
+$1.67M
3
Millennium Management
Millennium Management
New York
+$1.02M
4
Goldman Sachs
Goldman Sachs
New York
+$466K
5
Two Sigma Advisers
Two Sigma Advisers
New York
+$321K

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$4.03M
2
APM
Avidity Partners Management
Texas
-$3.74M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$408K
4
UBS AM
UBS AM
Illinois
-$248K
5
Jane Street
Jane Street
New York
-$192K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
26
Citigroup
New York
$81.5K -$78.4K -32,920 -46%
OQS
27
Occudo Quantitative Strategies
Florida
$76K -$5.55K -2,331 -6%
Northern Trust
28
Northern Trust
Illinois
$70.1K -$8.97K -3,768 -10%
Susquehanna International Group
29
Susquehanna International Group
Pennsylvania
$67.2K -$408K -171,605 -85%
CAPTRUST Financial Advisors
30
CAPTRUST Financial Advisors
North Carolina
$61.6K – – –
Dimensional Fund Advisors
31
Dimensional Fund Advisors
Texas
$54.1K -$30.9K -12,965 -34%
PAG
32
Private Advisor Group
New Jersey
$48.4K – – –
SSA
33
Schonfeld Strategic Advisors
New York
$46.8K +$51.8K +21,774 New
UBS Group
34
UBS Group
Switzerland
$37.6K -$4.98K -2,091 -11%
Morgan Stanley
35
Morgan Stanley
New York
$37.5K +$31.7K +13,297 +319%
Bank of America
36
Bank of America
North Carolina
$33.6K +$1.58K +664 +4%
Renaissance Technologies
37
Renaissance Technologies
New York
$30.7K +$34K +14,300 New
CSS
38
Cubist Systematic Strategies
Connecticut
$27.6K +$30.5K +12,825 New
Qube Research & Technologies (QRT)
39
Qube Research & Technologies (QRT)
United Kingdom
$21.9K -$95.6K -40,179 -80%
TRCT
40
Tower Research Capital (TRC)
New York
$11.6K +$10.2K +4,293 +386%
Royal Bank of Canada
41
Royal Bank of Canada
Ontario, Canada
$6K +$6.69K +2,812 New
JP Morgan Chase
42
JP Morgan Chase
New York
$2.19K +$2.43K +1,020 New
Federated Hermes
43
Federated Hermes
Pennsylvania
$1.97K +$1.68K +706 +335%
Osaic Holdings
44
Osaic Holdings
Arizona
$645 – – –
RhumbLine Advisers
45
RhumbLine Advisers
Massachusetts
$537 – – –
BI
46
BVF Inc
California
– -$4.03M -1,239,470 Closed
APM
47
Avidity Partners Management
Texas
– -$3.74M -1,150,000 Closed
UBS AM
48
UBS AM
Illinois
– -$248K -76,200 Closed
Jane Street
49
Jane Street
New York
– -$192K -59,166 Closed
LCM
50
Laurion Capital Management
New York
– -$142K -43,814 Closed
1
2
3

ANTX Hedge Fund Activity: Q2 2024 in Review

45 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in AN2 Therapeutics (ANTX) for Q2 2024, worth a combined $41.7M — down 31% from $60.9M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of ANTX and 6 opened new positions — a net loss of 8 holders — while 13 trimmed existing stakes and 14 added.

The largest buyer was Octagon Capital Advisors, adding an estimated $5.04M. The largest seller was BVF Inc, exiting entirely with an estimated $4.03M sold.

  • 45 institutional investors held AN2 Therapeutics (ANTX) as of Q2 2024, down from 54 in Q1 2024.
  • Funds reported $41.7M of AN2 Therapeutics stock for Q2 2024, down 31% quarter-over-quarter.
  • 6 funds opened new AN2 Therapeutics positions in Q2 2024 and 14 closed out, a net change of -8 holders.
  • The largest AN2 Therapeutics buyer in Q2 2024 was Octagon Capital Advisors, an estimated $5.04M added.
  • The largest AN2 Therapeutics seller in Q2 2024 was BVF Inc, an estimated $4.03M sold.

Based on aggregated 13F filings for Q2 2024.